- US Top Banks Warn Congress on 'Break-Up' Risks
- Obama Nudges Hu on Yuan; to Ease Trade Tensions
- UBS Targets $15 Billion Annual Profit in Mid-Term
- Fed's Kohn Sees No Asset Bubbles Building in US
- Buffett's Berkshire Hathaway Boosts Stake in Wal-Mart
- Microsoft Co-founder Allen Diagnosed with Cancer
- Time Warner to Spin Off AOL on December 9
- Gates Boosts Waste Management, Coca Cola Stakes
- US Cities With Most Underwater Mortgages
- Answers to Your Questions: A Path to Economic Disaster?
- 5 Ways to Play the Chinese Markets: Analyst
- Meredith Whitney: Turns Bearish
- 3 Stock Plays on Rising College Costs
- Warren Buffett's Berkshire Hathaway Almost Doubles Wal-Mart Holdings During Summer
- Nov. 16: Unusual Volume Leaders
- Getting to the Heart of the Merck-Abbott Embargo Break
- What MGM's Sale Could Say About Value of Content
- My Ratings on Lowe's & Home Depot: Analyst
- Gazprom says gas demand to pick up next year
- AP IMPACT: Tobacco execs quickly find tax loophole
- Budget airline easyJet FY profit down 14 percent
- Burberry Group PLC 1st-half profit down 24 percent
- Business foes of health care revamp ramp up effort
- Job prospects drawing students to ag schools
- Tajikistan bans production of standard light bulbs
- Cable and Wireless to split in 2 by March 31
- Singapore's exports stumble in October
Text Size 
CAMBRIDGE, Mass. - RNA drug developer Alnylam Pharmaceuticals Inc. reported a deeper third-quarter loss on Wednesday, primarily due to increased spending on stock based compensation and legal costs.
The biopharmaceutical company said it lost $9.2 million, or 22 cents per share, compared with a loss of $2.9 million, or 7 cents per share, a year ago. Its revenue slid 6 percent, to $24.2 percent from $25.7 million. All the company's revenue comes from research collaborations, as it has no products on the market.
According to Thomson Reuters, analysts expected Alnylam to lose 24 cents per share, with revenue of $26.3 million.
During the third quarter, its research and development costs increased 5 percent, to $23.2 million, and general and administrative costs climbed 56 percent to $10.7 million from $6.9 million.
Alnylam is developing drugs that use "gene silencing" technology, which is designed to turn off the protein that causes a disease. The company is partnering with Roche AG, Biogen Idec Inc., Cubist Pharmaceuticals Inc., Novartis AG, and the National Institutes of Health. Its products include potential treatments for respiratory disease, liver cancer, and the movement disorder Huntington's disease.
In aftermarket trading, Alnylam stock added 7 cents to $17.50 from from the regular session close of $17.43.
Print
Email
- Where, what, how.
- CNBC's Jim Goldman asks: Has the sun begun to set on Twitter? Data suggests its best days are over.
- Everyone wanted a piece of Madoff's "Bullship"--the famous buoy sold for $7,500 at auction. You won't believe these prices.
- De Loach Vineyards is selling its pinot noir the old fashioned way, helping to cut energy and transportation costs.
- Why are the Chinese concerned about the progress of U.S. health care legislation?
- CNBC's Maria Bartiromo talks to rapper Snoop Dogg about brand identity in both business and music.
Data is a real-time snapshot *Data is delayed at least 15 minutes